Literature DB >> 23126247

Why is publication of negative clinical trial data important?

Ann Hayes, Jackie Hunter.   

Abstract

Mesh：

Year:  2012        PMID： 23126247      PMCID： PMC3514755          DOI： 10.1111/j.1476-5381.2012.02215.x

Source DB:  PubMed          Journal:  Br J Pharmacol        ISSN： 0007-1188            Impact factor:   8.739


× No keyword cloud information.
  8 in total

Review 1.  How to improve R&D productivity: the pharmaceutical industry's grand challenge.

Authors:  Steven M Paul; Daniel S Mytelka; Christopher T Dunwiddie; Charles C Persinger; Bernard H Munos; Stacy R Lindborg; Aaron L Schacht
Journal:  Nat Rev Drug Discov       Date:  2010-02-19       Impact factor: 84.694

2.  Trial Registration at ClinicalTrials.gov between May and October 2005.

Authors:  Deborah A Zarin; Tony Tse; Nicholas C Ide
Journal:  N Engl J Med       Date:  2005-12-29       Impact factor: 91.245

Review 3.  Drug development for CNS disorders: strategies for balancing risk and reducing attrition.

Authors:  Menelas N Pangalos; Lee E Schechter; Orest Hurko
Journal:  Nat Rev Drug Discov       Date:  2007-07       Impact factor: 84.694

4.  Trial watch: Phase II failures: 2008-2010.

Authors:  John Arrowsmith
Journal:  Nat Rev Drug Discov       Date:  2011-05       Impact factor: 84.694

5.  Trial watch: phase III and submission failures: 2007-2010.

Authors:  John Arrowsmith
Journal:  Nat Rev Drug Discov       Date:  2011-02       Impact factor: 84.694

6.  Believe it or not: how much can we rely on published data on potential drug targets?

Authors:  Florian Prinz; Thomas Schlange; Khusru Asadullah
Journal:  Nat Rev Drug Discov       Date:  2011-08-31       Impact factor: 84.694

Review 7.  The vanilloid receptor TRPV1: 10 years from channel cloning to antagonist proof-of-concept.

Authors:  Arpad Szallasi; Daniel N Cortright; Charles A Blum; Samer R Eid
Journal:  Nat Rev Drug Discov       Date:  2007-05       Impact factor: 84.694

8.  The effects of the TRPV1 antagonist SB-705498 on TRPV1 receptor-mediated activity and inflammatory hyperalgesia in humans.

Authors:  Boris A Chizh; Mary B O'Donnell; Antonella Napolitano; Jie Wang; Allison C Brooke; Mike C Aylott; Jonathan N Bullman; Emily J Gray; Robert Y Lai; Pauline M Williams; Jonathan M Appleby
Journal:  Pain       Date:  2007-07-30       Impact factor: 6.961
  8 in total
  3 in total

Review 1.  The need for new approaches in CNS drug discovery: Why drugs have failed, and what can be done to improve outcomes.

Authors:  Valentin K Gribkoff; Leonard K Kaczmarek
Journal:  Neuropharmacology       Date:  2016-03-12       Impact factor: 5.250

Review 2.  Negative results: negative perceptions limit their potential for increasing reproducibility.

Authors:  Jaime A Teixeira da Silva
Journal:  J Negat Results Biomed       Date:  2015-07-07

3.  Clinical trial design and new therapies for pulmonary arterial hypertension.

Authors:  Olivier Sitbon; Mardi Gomberg-Maitland; John Granton; Michael I Lewis; Stephen C Mathai; Maurizio Rainisio; Norman L Stockbridge; Martin R Wilkins; Roham T Zamanian; Lewis J Rubin
Journal:  Eur Respir J       Date:  2019-01-24       Impact factor: 16.671
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.